RPL17 and autoimmune disease: Before treatment with PD - 1/PD - L1 inhibitors, patients should be carefully questioned about their history of endocrine and autoimmune diseases, undergo reasonable baseline screening, regularly monitor changes in endocrine indicators, and be more vigilant about possible related symptoms and signs to detect and handle irAEs as early as possible.